Depression in neurological disorders: An update

Current Opinion in Psychiatry

Volumn 19, Issue 3, 2006, Pages 294-298

  Rickards, Hugh ^a  

^a QUEEN ELIZABETH PSYCHIATRIC HOSPITAL   (United Kingdom)

Author keywords

Brain injury; Depression; Epilepsy; Multiple sclerosis; Parkinson's disease

Indexed keywords

BRAIN INJURY; COMMUNICATION DISORDER; DEGENERATIVE DISEASE; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DISEASE SEVERITY; EMOTION; EPILEPSY; HUMAN; MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; NEUROLOGY; REVIEW;

BRAIN INJURIES; DEPRESSIVE DISORDER; EPILEPSY; HUMANS; MULTIPLE SCLEROSIS; NERVOUS SYSTEM DISEASES; PARKINSON DISEASE;

EID: 33748136385     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.yco.0000218601.17722.5b     Document Type: Review

References (35)

1. Veazey C, Aki SOE, Cook KF, et al. Prevalence and treatment of depression in Parkinson's disease. J Neuropsychiatry Clin Neurosci 2005; 17:310-323. This study summarizes the current studies on the epidemiology of depression in Parkinson's disease as well as any treatment trials.
2. Leentjens AF, Verhey FR, Luijckx GJ, et al. The validity of the Beck Depression Inventory as a screening and diagnostic instrument for depression in patients with Parkinson's disease. Mov Disord 2000; 15:1221-1224.
3. Weintraub D, Newberg AB, Cary MS, et al. Striatal dopamine transporter imaging correlates with anxiety and depression symptoms in Parkinson's disease. J Nucl Med 2004; 46:227-232.
4. Mergl R, Mavrogiorgou P, Hegeri U, et al. Kinematic analysis of emotionally induced facial expressions: a novel tool to investigate hypomimia in patients suffering depression. J Neurol Neurosurg Psychiatry 2005; 76:138-140. This study looked at 25 depressed patients and measured facial expressions in response to funny cartoons using ultrasonic markers.
5. Leentjens AFG, Marinus J, Van Hilten JJ, et al. The contribution of somatic symptoms to the diagnosis of depressive disorder in Parkinson's disease: a discriminant analytic approach. J Neuropsychiatry Clin Neurosci 2003; 15:74-77.
6. Ertan FS, Ertan T, Kiziltan G, et al. Reliability and validity of the Geriatric Depression Scale in depression in Parkinson's disease. J Neurol Neurosurg Psychiatry 2005; 76:1445-1447.
7. Rodriguez-Oroz MC, Obeso JA, Lang AE, et al. Bilateral deep brain stimulation in Parkinson's disease: a multi-centre study with 4 years follow-up. Brain 2005; 128:2240-2249.
8. Chou KL, Hurtig HI, Jaggi-Jurg L, et al. Electro-convulsive therapy for depression in a Parkinson's disease patient with bilateral subthalamic nucleus deep brain stimulators. Parkinsonism Relat Disord 2005; 11:403-406.
9. Ghazi-Noori S, Chung TH, Dean KHO, et al. Therapies for depression in Parkinson's disease. Cochrane Database Syst Rev 2003; (2):CD003465.
10. Menza M, Marin H, Kaufman K, et al. Citalopram treatment of depression in Parkinson's disease: the impact on anxiety, disability and cognition. J Neuropsychiatry Clin Neurosci 2004; 16:315-319.
11. Deb S, Lyons I, Koutzoukis C, et al. Rate of psychiatric illness after traumatic brain injury. Am J Psychiatry 1999; 156:374-378.
12. Dikmen S, Bombadier CH, Machamer JE, et al. Natural history of depression in traumatic brain injury. Arch Phys Med Rehabil 2004; 85:1457-1463. A prospective study of 283 admissions for TBI that looks at rates of depression up to 5 years postinjury and examines risk factors.
13. Moldover JE, Goldberg KB, Prout MF. Depression after traumatic brain injury: a review of evidence for clinical heterogeneity. Neuropsychol Rev 2004; 14:143-153. A broad, conceptual view of depression after brain injury concluding that depression in this group represents a 'final common pathway' with a variety of contributing factors.
14. Jorge RE, Robinson RG, Moser D, et al. Major depression following traumatic brain injury. Arch Gen Psychiatry 2004; 61:42-50.
15. Levin HS, McCauley SR, Josic CP, et al. Predicting depression following mild traumatic brain injury. Arch Gen Psychiatry 2005; 62:523-528.
16. Rowland SM, Chow SL, Leahy B. Use of the Beck Depression Inventory-II (BDI-II) with persons with traumatic brain injury. Analysis of factorial structure. Brain Inj 2005; 19:77-83.
17. Turner-Stokes L, Kalmus M, Hirani, et al. The Depression Intensity Scale Circles (DISCs): a first evaluation of a simple assessment tool for depression in the context of brain injury. J Neurol Neurosurg Psychiatry 2005; 76:1273-1278. Describes the development and validation of an innovative scale for the measurement of depression in people who may have language or visuo-spatial difficulties.
18. Al-Adawi S, Dorvlo ASS, Burke DT, et al. Apathy and depression in cross-cultural survivors of traumatic brain injury. J Neuropsychiatry Clin Neurosci 2004; 16:435-442.
19. Lincoln N, Flanagan T. Cognitive behaviour therapy for the treatment of depression following stroke: a randomised controlled trial. Stroke 2003; 34:111-115.
20. Chwastiak L, Ehde DM, Gibbons LE, et al. Depressive symptoms and severity of illness in multiple sclerosis: an epidemiologic study of a large community sample. Am J Psychiatry 2002; 159:1862-1868.
21. Patten SB, Beck CA, Williams JV, et al. Major depression in multiple sclerosis: a population based perspective. Neurology 2003; 61:1524-1527.
22. Hart S, Fonareva I, Merluzzi N, et al. Treatment of depression and its relationship to improvement in quality of life and psychological well-being in multiple sclerosis patients. Qual Life Res 2005; 14:695-703.
23. Rupang P, Metz L, Patten S. Predictive value of CES-D in detecting depression among candidates for disease modifying multiple sclerosis treatment. Psychosomatics 2005; 46:131-134.
24. Moran P, Mohr D. The validity of Beck Depression Inventory and Hamilton Rating Scale for Depression items in the assessment of depression among patients with multiple sclerosis. J Behav Med 2005; 28:35-41. This study is interesting in that it shows how all the items in the BDI improve with treatment of depression in MS, including the vegetative or somatic items.
25. Gold R, Rieckmann P, Chang P, et al. The long-term safety and tolerability of high-dose interferon beta-1a in relapsing-remitting multiple sclerosis: 4-year data from the PRISMS study. Eur J Neurol 2005; 12:649-656.
26. Feinstein A, Roy P, Lobaugh N, et al. Structural brain abnormalities in multiple sclerosis patients with major depression. Neurology 2004; 62:586-590. This study compares depressed and nondepressed MS patients and identifies that left prefrontal lesions and high left anterior temporal volume account for 42% in the variance of depression scores.
27. Goldman Consensus Group. The Goldman Consensus statement on depression in multiple sclerosis. Mult Scler 2005; 11:328-337.
28. Gilliam FG. Diagnosis and treatment of mood disorders in persons with epilepsy. Curr Opin Neurol 2005; 18:129-133.
29. Loring DW, Meador KJ, Lee GP. Determinants of quality of life in epilepsy. Epilepsy Behav 2004; 5:976-980.
30. Ettinger A, Reed M, Cramer J. Depression and co-morbidity in community-based patients with epilepsy or asthma. Neurology 2004; 63:1008-1014. In this study, prevalence of depression in epilepsy was ascertained in the community using the CES-D, and depression was seen to be part of a complex pattern of physical, mental and social disability.
31. Jones JE, Herman BP, Barry JJ, et al. Clinical assessment of axis I psychiatric morbidity in chronic epilepsy: a multi-centre investigation. J Neuropsychiatry Clin Neurosci 2005; 17:172-179.
32. Jones JE, Herman BP, Barry JJ, et al. Screening for major depression in epilepsy with common self-report depression inventories. Epilepsia 2005; 46:731-735.
33. Thapar AJ, Roland M, Harold G. Do depression symptoms predict seizure frequency or vice versa? J Psychosom Res 2005; 59:269-274.
34. Kuhn KU, Quednow BB, Thiel M, et al. Antidepressive treatment in patients with temporal lobe epilepsy and major depression: a prospective study with three different antidepressants. Epilepsy Behav 2003; 4:674-679.
35. Specchio LM, Iudice A, Specchio N, et al. Citalopram as treatment of depression in patients with epilepsy. Clin Neuropharmacol 2004; 27:133-136.